<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240827021413&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240827021413&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 27 Aug 2024 06:14:14 +0000</lastbuilddate>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Novel Mouse Model of Late-Stage Coronary Atherosclerosis With Features of Plaque Rupture and Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):706-709. doi: 10.1161/CIRCULATIONAHA.124.070464. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186532</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070464>10.1161/CIRCULATIONAHA.124.070464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186532</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Constance Delwarde</dc:creator>
<dc:creator>Masanori Aikawa</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Mouse Model of Late-Stage Coronary Atherosclerosis With Features of Plaque Rupture and Stroke</dc:title>
<dc:identifier>pmid:39186532</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070464</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186531/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):736-737. doi: 10.1161/CIRCULATIONAHA.124.071606. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186531/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186531</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071606>10.1161/CIRCULATIONAHA.124.071606</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186531</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:39186531</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071606</dc:identifier>
</item>
<item>
<title>Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):724-735. doi: 10.1161/CIRCULATIONAHA.123.067957. Epub 2024 Aug 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional medications. DNA- and RNA-based therapeutics have the potential to transform the care of patients with FH. Recent advances are overcoming obstacles to clinical translation of nucleic acid-based medications, including greater stability of the formulations as well as site-specific delivery, making gene-based therapy for FH an alternative approach for treatment of FH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186530</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067957>10.1161/CIRCULATIONAHA.123.067957</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186530</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tulsi R Damase</dc:creator>
<dc:creator>Roman Sukhovershin</dc:creator>
<dc:creator>Biana Godin</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>John P Cooke</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia</dc:title>
<dc:identifier>pmid:39186530</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067957</dc:identifier>
</item>
<item>
<title>BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186529/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):738-741. doi: 10.1161/CIRCULATIONAHA.123.067438. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186529/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186529</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067438>10.1161/CIRCULATIONAHA.123.067438</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186529</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mariaelena Valentino</dc:creator>
<dc:creator>Matteo Malinverno</dc:creator>
<dc:creator>Claudio Maderna</dc:creator>
<dc:creator>Van-Cuong Pham</dc:creator>
<dc:creator>Claudia Jasmin Rödel</dc:creator>
<dc:creator>Federica Zanardi</dc:creator>
<dc:creator>Maximiliano Arce</dc:creator>
<dc:creator>Lorenzo Drufuca</dc:creator>
<dc:creator>Grazisa Rossetti</dc:creator>
<dc:creator>Peetra U Magnusson</dc:creator>
<dc:creator>Maria Grazia Lampugnani</dc:creator>
<dc:creator>Elisabetta Dejana</dc:creator>
<dc:creator>Salim Abdelilah-Seyfried</dc:creator>
<dc:creator>Massimiliano Pagani</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations</dc:title>
<dc:identifier>pmid:39186529</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067438</dc:identifier>
</item>
<item>
<title>Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):e201-e202. doi: 10.1161/CIRCULATIONAHA.124.069703. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186528</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069703>10.1161/CIRCULATIONAHA.124.069703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186528</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Puneeth Shridhar</dc:creator>
<dc:creator>Soumojit Pal</dc:creator>
<dc:creator>Nicolas G Clavere</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</dc:title>
<dc:identifier>pmid:39186528</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069703</dc:identifier>
</item>
<item>
<title>Perspectives on Heart Valve Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186527/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):661-662. doi: 10.1161/CIRCULATIONAHA.124.070262. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186527/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186527</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070262>10.1161/CIRCULATIONAHA.124.070262</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186527</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tirone E David</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Perspectives on Heart Valve Repair</dc:title>
<dc:identifier>pmid:39186527</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070262</dc:identifier>
</item>
<item>
<title>Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186526/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):e200. doi: 10.1161/CIRCULATIONAHA.123.068349. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186526/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186526</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068349>10.1161/CIRCULATIONAHA.123.068349</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186526</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Sun</dc:creator>
<dc:creator>Jian Ren</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</dc:title>
<dc:identifier>pmid:39186526</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068349</dc:identifier>
</item>
<item>
<title>Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-Cd36^(fl/-) mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):710-723. doi: 10.1161/CIRCULATIONAHA.123.065005. Epub 2024 Aug 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell-derived exosome nebulization therapy (SCENT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stem cell-derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of <i>Cd36</i> in endothelial cells (ECs). In an EC-<i>Cd36</i><sup>fl/-</sup> conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-<i>Cd36</i><sup>fl/-</sup> mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39186525</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065005>10.1161/CIRCULATIONAHA.123.065005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186525</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Junlang Li</dc:creator>
<dc:creator>Shenghuan Sun</dc:creator>
<dc:creator>Dashuai Zhu</dc:creator>
<dc:creator>Xuan Mei</dc:creator>
<dc:creator>Yongbo Lyu</dc:creator>
<dc:creator>Ke Huang</dc:creator>
<dc:creator>Yuan Li</dc:creator>
<dc:creator>Shuo Liu</dc:creator>
<dc:creator>Zhenzhen Wang</dc:creator>
<dc:creator>Shiqi Hu</dc:creator>
<dc:creator>Halle J Lutz</dc:creator>
<dc:creator>Kristen D Popowski</dc:creator>
<dc:creator>Phuong-Uyen C Dinh</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Ke Cheng</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction</dc:title>
<dc:identifier>pmid:39186525</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065005</dc:identifier>
</item>
<item>
<title>Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae479. doi: 10.1093/eurheartj/ehae479. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with placebo (saline) in 200 patients with symptomatic HFpEF and ID (serum ferritin &lt; 100 ng/mL or ferritin 100-299 ng/mL with transferrin saturation &lt; 20%). The primary endpoint was change in 6-min walking test distance (6MWTD) from baseline to week 24. Secondary endpoints included changes in New York Heart Association class, patient global assessment, and health-related quality of life (QoL).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial was stopped because of slow recruitment after 39 patients had been included (median age 80 years, 62% women). The change in 6MWTD from baseline to week 24 was greater for those assigned to FCM compared to placebo [least square mean difference 49 m, 95% confidence interval (CI) 5-93; P = .029]. Changes in secondary endpoints were not significantly different between groups. The total number of adverse events (76 vs. 114) and serious adverse events (5 vs. 19; rate ratio 0.27, 95% CI 0.07-0.96; P = .043) was lower with FCM than placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39185895</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae479>10.1093/eurheartj/ehae479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185895</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephan von Haehling</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Ruben Evertz</dc:creator>
<dc:creator>Tania Garfias-Veitl</dc:creator>
<dc:creator>Carlotta Derad</dc:creator>
<dc:creator>Monika Diek</dc:creator>
<dc:creator>Mahir Karakas</dc:creator>
<dc:creator>Ralf Birkemeyer</dc:creator>
<dc:creator>Gerasimos Fillippatos</dc:creator>
<dc:creator>Mitja Lainscak</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial</dc:title>
<dc:identifier>pmid:39185895</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae479</dc:identifier>
</item>
<item>
<title>Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae490. doi: 10.1093/eurheartj/ehae490. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39185864</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae490>10.1093/eurheartj/ehae490</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185864</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?</dc:title>
<dc:identifier>pmid:39185864</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae490</dc:identifier>
</item>
<item>
<title>Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae525. doi: 10.1093/eurheartj/ehae525. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To explore male-female differences in aneurysm growth and clinical outcomes in a two-centre retrospective Dutch cohort study of adult patients with ascending aortic aneurysm (AscAA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adult patients in whom imaging of an AscAA (root and/or ascending: ≥40 mm) was performed between 2007 and 2022 were included. Aneurysm growth was analysed using repeated measurements at the sinuses of Valsalva (SoV) and tubular ascending aorta. Male-female differences were explored in presentation, aneurysm characteristics, treatment strategy, survival, and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: One thousand eight hundred and fifty-eight patients were included (31.6% female). Median age at diagnosis was 65.4 years (interquartile range: 53.4-71.7) for females and 59.0 years (interquartile range: 49.3-68.0) for males (P &lt; .001). At diagnosis, females more often had tubular ascending aortic involvement (75.5% vs. 70.2%; P = .030) while males more often had SoV involvement (42.8% vs. 21.6%; P &lt; .001). Maximum absolute aortic diameter, at any location, at diagnosis did not differ between females (45.0 mm) and males (46.5 mm; P = .388). In females, tubular ascending growth was faster (P &lt; .001), whereas in males, SoV growth was faster (P = .005), corrected for covariates. Unadjusted 10-year survival was 72.5% [95% confidence interval (CI) 67.8%-77.6%] for females and 78.3% (95% CI 75.3%-81.3%) for males (P = .010). Twenty-three type A dissections occurred, with an incidence rate of 8.2/1000 patient-years (95% CI 4.4-14.1) in females and 2.4/1000 patient-years (95% CI 1.2-4.5) in males [incidence rate ratio females/males: 3.4 (95% CI 1.5-8.0; P = .004)].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39185705</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae525>10.1093/eurheartj/ehae525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185705</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Maximiliaan L Notenboom</dc:creator>
<dc:creator>Adine R de Keijzer</dc:creator>
<dc:creator>Kevin M Veen</dc:creator>
<dc:creator>Arjen Gökalp</dc:creator>
<dc:creator>Ad J J C Bogers</dc:creator>
<dc:creator>Robin H Heijmen</dc:creator>
<dc:creator>Roland R J van Kimmenade</dc:creator>
<dc:creator>Guillaume S C Geuzebroek</dc:creator>
<dc:creator>M Mostafa Mokhles</dc:creator>
<dc:creator>Jos A Bekkers</dc:creator>
<dc:creator>Jolien W Roos-Hesselink</dc:creator>
<dc:creator>Johanna J M Takkenberg</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study</dc:title>
<dc:identifier>pmid:39185705</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae525</dc:identifier>
</item>
<item>
<title>Microtubules Sequester Acetylated YAP in the Cytoplasm and Inhibit Heart Regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: After myocardial infarction, decreased sirtuin activity enriches YAP acetylation at K265. The growing TUBA4A network sequesters acetylated YAP within the cytoplasm, which is detrimental to cardiac regeneration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.067646. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Hippo pathway effector YAP (Yes-associated protein) plays an essential role in cardiomyocyte proliferation and heart regeneration. In response to physiological changes, YAP moves in and out of the nucleus. The pathophysiological mechanisms regulating YAP subcellular localization after myocardial infarction remain poorly defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We identified YAP acetylation at site K265 by in vitro acetylation followed by mass spectrometry analysis. We used adeno-associated virus to express YAP-containing mutations that either abolished acetylation (YAP-K265R) or mimicked acetylation (YAP-K265Q) and studied how acetylation regulates YAP subcellular localization in mouse hearts. We generated a cell line with YAP-K265R mutation and investigated the protein-protein interactors by YAP immunoprecipitation followed by mass spectrometry, then validated the YAP interaction in neonatal rat ventricular myocytes. We examined colocalization of YAP and TUBA4A (tubulin α 4A) by superresolution imaging. Furthermore, we developed YAP-K265R and <i>αMHC-MerCreMer (MCM); Yap-loxP/K265R</i> mutant mice to examine the pathophysiological role of YAP acetylation in cardiomyocytes during cardiac regeneration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that YAP is acetylated at K265 by CBP (CREB-binding protein)/P300 (E1A-binding protein P300) and is deacetylated by nicotinamide phosphoribosyltransferase/nicotinamide adenine dinucleotide/sirtuins axis in cardiomyocytes. After myocardial infarction, YAP acetylation is increased, which promotes YAP cytoplasmic localization. Compared with controls, mice that were genetically engineered to express a K265R mutation that prevents YAP K256 acetylation showed improved cardiac regenerative ability and increased YAP nuclear localization. Mechanistically, YAP acetylation facilitates its interaction with TUBA4A, a component of the microtubule network that sequesters acetylated YAP in the cytoplasm. After myocardial infarction, the microtubule network increased in cardiomyocytes, resulting in the accumulation of YAP in the cytoplasm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After myocardial infarction, decreased sirtuin activity enriches YAP acetylation at K265. The growing TUBA4A network sequesters acetylated YAP within the cytoplasm, which is detrimental to cardiac regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39185559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067646>10.1161/CIRCULATIONAHA.123.067646</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185559</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Shijie Liu</dc:creator>
<dc:creator>Vaibhav Deshmukh</dc:creator>
<dc:creator>Fansen Meng</dc:creator>
<dc:creator>Yidan Wang</dc:creator>
<dc:creator>Yuka Morikawa</dc:creator>
<dc:creator>Jeffery D Steimle</dc:creator>
<dc:creator>Rich Gang Li</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Microtubules Sequester Acetylated YAP in the Cytoplasm and Inhibit Heart Regeneration</dc:title>
<dc:identifier>pmid:39185559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067646</dc:identifier>
</item>
<item>
<title>The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39181133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Chromothripsis describes the catastrophic shattering of mis-segregated chromosomes trapped within micronuclei. Although micronuclei accumulate DNA double-strand breaks and replication defects throughout interphase, how chromosomes undergo shattering remains unresolved. Using CRISPR-Cas9 screens, we identify a non-canonical role of the Fanconi anemia (FA) pathway as a driver of chromothripsis. Inactivation of the FA pathway suppresses chromosome shattering during mitosis without impacting...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 20:S0092-8674(24)00892-4. doi: 10.1016/j.cell.2024.08.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chromothripsis describes the catastrophic shattering of mis-segregated chromosomes trapped within micronuclei. Although micronuclei accumulate DNA double-strand breaks and replication defects throughout interphase, how chromosomes undergo shattering remains unresolved. Using CRISPR-Cas9 screens, we identify a non-canonical role of the Fanconi anemia (FA) pathway as a driver of chromothripsis. Inactivation of the FA pathway suppresses chromosome shattering during mitosis without impacting interphase-associated defects within micronuclei. Mono-ubiquitination of FANCI-FANCD2 by the FA core complex promotes its mitotic engagement with under-replicated micronuclear chromosomes. The structure-selective SLX4-XPF-ERCC1 endonuclease subsequently induces large-scale nucleolytic cleavage of persistent DNA replication intermediates, which stimulates POLD3-dependent mitotic DNA synthesis to prime shattered fragments for reassembly in the ensuing cell cycle. Notably, FA-pathway-induced chromothripsis generates complex genomic rearrangements and extrachromosomal DNA that confer acquired resistance to anti-cancer therapies. Our findings demonstrate how pathological activation of a central DNA repair mechanism paradoxically triggers cancer genome evolution through chromothripsis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39181133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39181133</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.001>10.1016/j.cell.2024.08.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39181133</guid>
<pubDate>Sat, 24 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Justin L Engel</dc:creator>
<dc:creator>Xiao Zhang</dc:creator>
<dc:creator>Mingming Wu</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Jose Espejo Valle-Inclán</dc:creator>
<dc:creator>Qing Hu</dc:creator>
<dc:creator>Kidist S Woldehawariat</dc:creator>
<dc:creator>Mathijs A Sanders</dc:creator>
<dc:creator>Agata Smogorzewska</dc:creator>
<dc:creator>Jin Chen</dc:creator>
<dc:creator>Isidro Cortés-Ciriano</dc:creator>
<dc:creator>Roger S Lo</dc:creator>
<dc:creator>Peter Ly</dc:creator>
<dc:date>2024-08-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance</dc:title>
<dc:identifier>pmid:39181133</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.001</dc:identifier>
</item>
<item>
<title>Thyroid hormone remodels cortex to coordinate body-wide metabolism and exploration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Animals adapt to environmental conditions by modifying the function of their internal organs, including the brain. To be adaptive, alterations in behavior must be coordinated with the functional state of organs throughout the body. Here, we find that thyroid hormone-a regulator of metabolism in many peripheral organs-directly activates cell-type-specific transcriptional programs in the frontal cortex of adult male mice. These programs are enriched for axon-guidance genes in glutamatergic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 19:S0092-8674(24)00835-3. doi: 10.1016/j.cell.2024.07.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Animals adapt to environmental conditions by modifying the function of their internal organs, including the brain. To be adaptive, alterations in behavior must be coordinated with the functional state of organs throughout the body. Here, we find that thyroid hormone-a regulator of metabolism in many peripheral organs-directly activates cell-type-specific transcriptional programs in the frontal cortex of adult male mice. These programs are enriched for axon-guidance genes in glutamatergic projection neurons, synaptic regulatory genes in both astrocytes and neurons, and pro-myelination factors in oligodendrocytes, suggesting widespread plasticity of cortical circuits. Indeed, whole-cell electrophysiology revealed that thyroid hormone alters excitatory and inhibitory synaptic transmission, an effect that requires thyroid hormone-induced gene regulatory programs in presynaptic neurons. Furthermore, thyroid hormone action in the frontal cortex regulates innate exploratory behaviors and causally promotes exploratory decision-making. Thus, thyroid hormone acts directly on the cerebral cortex in males to coordinate exploratory behaviors with whole-body metabolic state.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178853</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.041>10.1016/j.cell.2024.07.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178853</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel R Hochbaum</dc:creator>
<dc:creator>Lauren Hulshof</dc:creator>
<dc:creator>Amanda Urke</dc:creator>
<dc:creator>Wengang Wang</dc:creator>
<dc:creator>Alexandra C Dubinsky</dc:creator>
<dc:creator>Hannah C Farnsworth</dc:creator>
<dc:creator>Richard Hakim</dc:creator>
<dc:creator>Sherry Lin</dc:creator>
<dc:creator>Giona Kleinberg</dc:creator>
<dc:creator>Keiramarie Robertson</dc:creator>
<dc:creator>Canaria Park</dc:creator>
<dc:creator>Alyssa Solberg</dc:creator>
<dc:creator>Yechan Yang</dc:creator>
<dc:creator>Caroline Baynard</dc:creator>
<dc:creator>Naeem M Nadaf</dc:creator>
<dc:creator>Celia C Beron</dc:creator>
<dc:creator>Allison E Girasole</dc:creator>
<dc:creator>Lynne Chantranupong</dc:creator>
<dc:creator>Marissa D Cortopassi</dc:creator>
<dc:creator>Shannon Prouty</dc:creator>
<dc:creator>Ludwig Geistlinger</dc:creator>
<dc:creator>Alexander S Banks</dc:creator>
<dc:creator>Thomas S Scanlan</dc:creator>
<dc:creator>Sandeep Robert Datta</dc:creator>
<dc:creator>Michael E Greenberg</dc:creator>
<dc:creator>Gabriella L Boulting</dc:creator>
<dc:creator>Evan Z Macosko</dc:creator>
<dc:creator>Bernardo L Sabatini</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Thyroid hormone remodels cortex to coordinate body-wide metabolism and exploration</dc:title>
<dc:identifier>pmid:39178853</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.041</dc:identifier>
</item>
<item>
<title>Memory B cell fitness and anergy has significant links to cancer lethality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Two recent studies reveal that the extent of fitness or anergy in tumor-associated memory B cells is vital to anti-tumor immune response, cancer patient survival, and response to immune therapy. The impact of these seminal findings demonstrates the untapped potential for using B cells to combat the lethality of cancer.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4551-4553. doi: 10.1016/j.cell.2024.07.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Two recent studies reveal that the extent of fitness or anergy in tumor-associated memory B cells is vital to anti-tumor immune response, cancer patient survival, and response to immune therapy. The impact of these seminal findings demonstrates the untapped potential for using B cells to combat the lethality of cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178833</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.037>10.1016/j.cell.2024.07.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178833</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Hollern</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Memory B cell fitness and anergy has significant links to cancer lethality</dc:title>
<dc:identifier>pmid:39178833</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.037</dc:identifier>
</item>
<item>
<title>OLAH connects fatty acid metabolism to the severity of respiratory viral disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Respiratory virus infections may cause profound respiratory illness, yet the factors that underlie disease severity are not well understood. In this issue of Cell, Jia, Crawford, et al.¹ identify the role of oleoyl-ACP-hydrolase (OLAH) in mediating life-threatening inflammation associated with viral respiratory disease severity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4549-4551. doi: 10.1016/j.cell.2024.07.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Respiratory virus infections may cause profound respiratory illness, yet the factors that underlie disease severity are not well understood. In this issue of Cell, Jia, Crawford, et al.<sup>1</sup> identify the role of oleoyl-ACP-hydrolase (OLAH) in mediating life-threatening inflammation associated with viral respiratory disease severity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178832</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.032>10.1016/j.cell.2024.07.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178832</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Palanki</dc:creator>
<dc:creator>Hannah Yamagata</dc:creator>
<dc:creator>Michael J Mitchell</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>OLAH connects fatty acid metabolism to the severity of respiratory viral disease</dc:title>
<dc:identifier>pmid:39178832</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.032</dc:identifier>
</item>
<item>
<title>Toward a foundation model of causal cell and tissue biology with a Perturbation Cell and Tissue Atlas</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Comprehensively charting the biologically causal circuits that govern the phenotypic space of human cells has often been viewed as an insurmountable challenge. However, in the last decade, a suite of interleaved experimental and computational technologies has arisen that is making this fundamental goal increasingly tractable. Pooled CRISPR-based perturbation screens with high-content molecular and/or image-based readouts are now enabling researchers to probe, map, and decipher genetically causal...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4520-4545. doi: 10.1016/j.cell.2024.07.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Comprehensively charting the biologically causal circuits that govern the phenotypic space of human cells has often been viewed as an insurmountable challenge. However, in the last decade, a suite of interleaved experimental and computational technologies has arisen that is making this fundamental goal increasingly tractable. Pooled CRISPR-based perturbation screens with high-content molecular and/or image-based readouts are now enabling researchers to probe, map, and decipher genetically causal circuits at increasing scale. This scale is now eminently suitable for the deployment of artificial intelligence and machine learning (AI/ML) to both direct further experiments and to predict or generate information that was not-and sometimes cannot-be gathered experimentally. By combining and iterating those through experiments that are designed for inference, we now envision a Perturbation Cell Atlas as a generative causal foundation model to unify human cell biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178831</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.035>10.1016/j.cell.2024.07.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178831</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer E Rood</dc:creator>
<dc:creator>Anna Hupalowska</dc:creator>
<dc:creator>Aviv Regev</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Toward a foundation model of causal cell and tissue biology with a Perturbation Cell and Tissue Atlas</dc:title>
<dc:identifier>pmid:39178831</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.035</dc:identifier>
</item>
<item>
<title>Spatiotemporal omics for biology and medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>The completion of the Human Genome Project has provided a foundational blueprint for understanding human life. Nonetheless, understanding the intricate mechanisms through which our genetic blueprint is involved in disease or orchestrates development across temporal and spatial dimensions remains a profound scientific challenge. Recent breakthroughs in cellular omics technologies have paved new pathways for understanding the regulation of genomic elements and the relationship between gene...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4488-4519. doi: 10.1016/j.cell.2024.07.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The completion of the Human Genome Project has provided a foundational blueprint for understanding human life. Nonetheless, understanding the intricate mechanisms through which our genetic blueprint is involved in disease or orchestrates development across temporal and spatial dimensions remains a profound scientific challenge. Recent breakthroughs in cellular omics technologies have paved new pathways for understanding the regulation of genomic elements and the relationship between gene expression, cellular functions, and cell fate determination. The advent of spatial omics technologies, encompassing both imaging and sequencing-based methodologies, has enabled a comprehensive understanding of biological processes from a cellular ecosystem perspective. This review offers an updated overview of how spatial omics has advanced our understanding of the translation of genetic information into cellular heterogeneity and tissue structural organization and their dynamic changes over time. It emphasizes the discovery of various biological phenomena, related to organ functionality, embryogenesis, species evolution, and the pathogenesis of diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178830</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.040>10.1016/j.cell.2024.07.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178830</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Longqi Liu</dc:creator>
<dc:creator>Ao Chen</dc:creator>
<dc:creator>Yuxiang Li</dc:creator>
<dc:creator>Jan Mulder</dc:creator>
<dc:creator>Holger Heyn</dc:creator>
<dc:creator>Xun Xu</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spatiotemporal omics for biology and medicine</dc:title>
<dc:identifier>pmid:39178830</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.040</dc:identifier>
</item>
<item>
<title>Multiphoton fluorescence microscopy for in vivo imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Multiphoton fluorescence microscopy (MPFM) has been a game-changer for optical imaging, particularly for studying biological tissues deep within living organisms. MPFM overcomes the strong scattering of light in heterogeneous tissue by utilizing nonlinear excitation that confines fluorescence emission mostly to the microscope focal volume. This enables high-resolution imaging deep within intact tissue and has opened new avenues for structural and functional studies. MPFM has found widespread...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4458-4487. doi: 10.1016/j.cell.2024.07.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Multiphoton fluorescence microscopy (MPFM) has been a game-changer for optical imaging, particularly for studying biological tissues deep within living organisms. MPFM overcomes the strong scattering of light in heterogeneous tissue by utilizing nonlinear excitation that confines fluorescence emission mostly to the microscope focal volume. This enables high-resolution imaging deep within intact tissue and has opened new avenues for structural and functional studies. MPFM has found widespread applications and has led to numerous scientific discoveries and insights into complex biological processes. Today, MPFM is an indispensable tool in many research communities. Its versatility and effectiveness make it a go-to technique for researchers investigating biological phenomena at the cellular and subcellular levels in their native environments. In this Review, the principles, implementations, capabilities, and limitations of MPFM are presented. Three application areas of MPFM, neuroscience, cancer biology, and immunology, are reviewed in detail and serve as examples for applying MPFM to biological research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178829</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.036>10.1016/j.cell.2024.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178829</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Chris Xu</dc:creator>
<dc:creator>Maiken Nedergaard</dc:creator>
<dc:creator>Deborah J Fowell</dc:creator>
<dc:creator>Peter Friedl</dc:creator>
<dc:creator>Na Ji</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiphoton fluorescence microscopy for in vivo imaging</dc:title>
<dc:identifier>pmid:39178829</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.036</dc:identifier>
</item>
<item>
<title>The evolution of computational research in a data-centric world</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>Computational data-centric research techniques play a prevalent and multi-disciplinary role in life science research. In the past, scientists in wet labs generated the data, and computational researchers focused on creating tools for the analysis of those data. Computational researchers are now becoming more independent and taking leadership roles within biomedical projects, leveraging the increased availability of public data. We are now able to generate vast amounts of data, and the challenge...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4449-4457. doi: 10.1016/j.cell.2024.07.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Computational data-centric research techniques play a prevalent and multi-disciplinary role in life science research. In the past, scientists in wet labs generated the data, and computational researchers focused on creating tools for the analysis of those data. Computational researchers are now becoming more independent and taking leadership roles within biomedical projects, leveraging the increased availability of public data. We are now able to generate vast amounts of data, and the challenge has shifted from data generation to data analysis. Here we discuss the pitfalls, challenges, and opportunities facing the field of data-centric research in biology. We discuss the evolving perception of computational data-driven research and its rise as an independent domain in biomedical research while also addressing the significant collaborative opportunities that arise from integrating computational research with experimental and translational biology. Additionally, we discuss the future of data-centric research and its applications across various areas of the biomedical field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178828</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.045>10.1016/j.cell.2024.07.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178828</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Dhrithi Deshpande</dc:creator>
<dc:creator>Karishma Chhugani</dc:creator>
<dc:creator>Tejasvene Ramesh</dc:creator>
<dc:creator>Matteo Pellegrini</dc:creator>
<dc:creator>Sagiv Shiffman</dc:creator>
<dc:creator>Malak S Abedalthagafi</dc:creator>
<dc:creator>Saleh Alqahtani</dc:creator>
<dc:creator>Jimmie Ye</dc:creator>
<dc:creator>Xiaole Shirley Liu</dc:creator>
<dc:creator>Jeffrey T Leek</dc:creator>
<dc:creator>Alvis Brazma</dc:creator>
<dc:creator>Roel A Ophoff</dc:creator>
<dc:creator>Gauri Rao</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Jason H Moore</dc:creator>
<dc:creator>Vsevolod Katritch</dc:creator>
<dc:creator>Serghei Mangul</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The evolution of computational research in a data-centric world</dc:title>
<dc:identifier>pmid:39178828</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.045</dc:identifier>
</item>
<item>
<title>In vitro human cell-based models: What can they do and what are their limitations?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178827/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240827021413&amp;v=2.18.0.post9+e462414
      <description>It is said that all models are wrong, but some are useful. In vitro human cell-based models are a prime example of this maxim. We asked researchers: when is your model system useful? How can it be made more useful? What are its limitations?</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4439-4443. doi: 10.1016/j.cell.2024.07.042.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">It is said that all models are wrong, but some are useful. In vitro human cell-based models are a prime example of this maxim. We asked researchers: when is your model system useful? How can it be made more useful? What are its limitations?</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178827/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240827021413&v=2.18.0.post9+e462414">39178827</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.042>10.1016/j.cell.2024.07.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178827</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthias P Lutolf</dc:creator>
<dc:creator>Milica Radisic</dc:creator>
<dc:creator>Jeffrey Beekman</dc:creator>
<dc:creator>Dan Dongeun Huh</dc:creator>
<dc:creator>Meritxell Huch</dc:creator>
<dc:creator>Margherita Yayoi Turco</dc:creator>
<dc:creator>Zeinab Niloofar Tahmasebi Birgani</dc:creator>
<dc:creator>Dong Gao</dc:creator>
<dc:creator>Rui Yao</dc:creator>
<dc:creator>Hang Lin</dc:creator>
<dc:creator>Takanori Takebe</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>In vitro human cell-based models: What can they do and what are their limitations?</dc:title>
<dc:identifier>pmid:39178827</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.042</dc:identifier>
</item>





























</channel>
</rss>